LAVECCHIA, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 88
AS - Asia 20
EU - Europa 15
Totale 123
Nazione #
US - Stati Uniti d'America 88
SG - Singapore 12
CN - Cina 7
SE - Svezia 6
DE - Germania 4
AT - Austria 1
BE - Belgio 1
FR - Francia 1
IE - Irlanda 1
KR - Corea 1
UA - Ucraina 1
Totale 123
Città #
Ashburn 15
Fairfield 12
Singapore 11
Woodbridge 10
Seattle 7
Nyköping 6
Wilmington 5
Houston 4
New York 4
Ann Arbor 3
Lawrence 3
Cambridge 2
Munich 2
Princeton 2
Santa Clara 2
Brussels 1
Des Moines 1
Dublin 1
Frankfurt am Main 1
Los Angeles 1
Paris 1
Roxbury 1
San Francisco 1
Seoul 1
Shanghai 1
Shenzhen 1
Xi'an 1
Totale 100
Nome #
Synthesis and Biological Evaluation of Pyrazoline and Pyrrolidine-2,5-dione Hybrids as Potential Antitumor Agents 47
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies. 37
A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition 20
A Chemical Modification of a Peroxisome Proliferator-Activated Receptor Pan Agonist Produced a Shift to a New Dual Alpha/Gamma Partial Agonist Endowed with Mitochondrial Pyruvate Carrier Inhibition and Antidiabetic Properties 16
Thiazolidinedione "magic Bullets" Simultaneously Targeting PPARγand HDACs: Design, Synthesis, and Investigations of their in Vitro and in Vivo Antitumor Effects 16
Discovery of a dual PPARα/γ partial agonist displaying antisteatotic and antidiabetic properties: in silico studies and X-ray structure determination 4
Totale 140
Categoria #
all - tutte 1.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.115


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202153 0 0 0 41 0 0 0 4 0 4 0 4
2021/202215 0 0 0 4 0 2 0 2 1 2 1 3
2022/202313 3 1 1 0 0 1 1 3 2 0 1 0
2023/202420 1 3 1 2 5 4 0 0 0 1 0 3
2024/202539 8 3 14 5 9 0 0 0 0 0 0 0
Totale 140